Stock Rating Upgrade
The Value Trend Rating for Zevra Therapeutics Inc (NASDAQ: ZVRA) improved recently from C to B reflecting improving fundamentals and high Appreciation Potential. Details supporting this higher rating are included in our next report.
Recent Price Action
Zevra Therapeutics Inc (NASDAQ: ZVRA) stock closed at $7.75 on 9/12/25 after a decline of -2.5%. Moreover, this decline was accompanied by above average trading volume at 122% of normal. The stock has declined -13.2% during the last week but has been strong relative to the market over the last nine months.
Current PriceTarget Research Rating
Zevra Therapeutics has a current Value Trend Rating of B (Positive). This VT Rating improved in recent days from C previously. With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing inconsistent signals. Zevra Therapeutics has a neutral Appreciation Score of 50 but a good Power Rating of 72, producing the Positive Value Trend Rating.
Be the first to comment